Clinical Trial Update: Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of ultra-low-dose total-skin electron beam therapy with Brentuximab Vedotin given quarterly over 12 months in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mycosis Fungoides

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Mycosis Fungoides | Phase 2 | Status: RECRUITING